To better understand how peptides are classified, studied, and regulated, visit our Research Library.
If you’ve noticed peptide supplier websites going dark over the past several months, it’s not a coincidence.
The FDA has issued multiple warning letters to research peptide companies, specifically those selling semaglutide, tirzepatide, and retatrutide, with products flagged as “unapproved drugs” and “misbranded.” Companies publicly named in warning letters include Excel Peptides, Swiss Chems, Summit Research, Prime Peptides, and USA Peptides.
The core issue isn’t just the “for research use only” disclaimer. Regulators are scrutinizing the gap between labeling language and the obvious intent of the marketing. When a product page looks like a weight loss clinic but carries an RUO disclaimer at the bottom, the FDA isn’t buying it.
This enforcement push is directly tied to the GLP-1 boom. As Ozempic and Wegovy became household names, demand for research-channel alternatives exploded, and so did regulatory attention. Retatrutide, which isn’t even FDA-approved yet, is now appearing in warning letters.
For the broader research peptide space, this is a signal worth watching. Companies with clean documentation standards, third-party tested products, and compliant marketing are in a very different position than those riding the GLP-1 wave without guardrails.